Operating Room

Henan’an, China

Operating Room

Henan’an, China

Time filter

Source Type

News Article | May 11, 2017
Site: globenewswire.com

CLEVELAND, May 11, 2017 (GLOBE NEWSWIRE) -- Mercury Biomed, a company developing a novel approach to managing core body temperature, announces it has won a non-dilutive Phase I Small Business Technology Transfer (STTR) grant through the National Institute of General Medical Sciences (NIGMS) for $225,000. The award (R41GM119871) will enable Mercury to accelerate commercialization of its first device, a disruptive solution for warming patients in the peri-operative environment. “Managing core body temperature safely and effectively in surgical procedures remains a big challenge, and Mercury’s air-free patient warming solution is designed for physicians and hospitals transitioning to value-based care and alternative payment models,” explains Brian Patrick, Mercury Co-Founder. Fifty three million patients undergo general anesthesia procedures each year and run the risk of life-threatening complications due to rapid reduction of core body temperature in the Operating Room. Warming patients during surgery has become standard of care, but Mercury’s approach is vastly different and considerably smarter than existing alternatives. Mercury’s WarmSmart system, in contrast to alternative methods, works in-concert with the body’s intrinsic thermoregulatory function to noninvasively warm the body core. WarmSmart is physiologically more efficient, less intrusive to the surgical field, easy-to-use, and eliminates the risk of surgical site infection associated with current forced-air warming devices. The global market for patient temperature management solutions is $2.5 billion per year. "Mercury is deeply appreciative of the assistance provided by the NIH and NIGMS through this STTR program," said Brad Pulver, CEO of Mercury Biomed. "Our mission is to provide the smartest, safest, and most clinically effective solution to help hospitals and surgeons who, in a growing number of cases, are required to accept financial responsibility for patient outcomes. This award expedites our time to market and allows us to continue our rapid progress and initial success toward this goal.” WarmSmart was developed from research conducted at The University of Texas at Austin. Professor Ken Diller, Inventor, Principal Investigator, and Mercury’s Chief Science Officer commented, “An award from this highly competitive STTR program is a testimony to the importance of improving safety and surgery outcomes, and our disruptive discovery for the field of human temperature management. The support of the NIH is validating to our efforts and will be instrumental in translating our technology from my bio heat transfer lab to commercial application." Based on the results achieved in Phase I and the scientific and technical merit and commercial potential of Mercury’s project, an additional potential $1.5M in non-dilutive funds may be awarded in Phase II.  During Phase II, Mercury would begin its second pivotal clinical trial with its partner, the Cleveland Clinic, where Drs. Daniel Sessler and Andrea Kurz, along with Dr. Wilton Levine (Mass General) will oversee Mercury’s clinical efforts. The grant is Mercury’s second major non-dilutive funding victory, as it was previously funded by the Ohio Third Frontier program, placing Mercury in rare company as a winner of both awards. About Mercury Biomed: Based in Cleveland, Ohio, Mercury Biomed, LLC is commercializing its proprietary Smart Temperature Management System™ technology, a breakthrough non-invasive and holistic approach to cooling and warming patients when and where it matters most. Founded in 2015, the company is led by top scientific experts and entrepreneurs in the field of therapeutic temperature management. Mercury Biomed’s WarmSmart product is currently in clinical trials and is targeted for a 2018 launch, pending FDA 510(k) clearance.  www.mercurybiomed.com About the National Institutes of Health (NIH) STTR & SBIR Programs: The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are designed to award federal research grants to small businesses conducting biomedical research. The goal of these Programs is to spur technological innovation leading to commercialization of novel innovative medical technologies to improve public health. Both Programs share this common goal, but differ somewhat in eligibility and research execution criteria. The NIH STTR and SBIR Programs are highly competitive, as reflected in the following award data statistics for Phase I STTR awards for fiscal years 2007-2016 available at https://sbir.nih.gov/statistics/award-data. For more information about the NIH STTR and SBIR Programs, please go to https://sbir.nih.gov/.


News Article | May 11, 2017
Site: globenewswire.com

CLEVELAND, May 11, 2017 (GLOBE NEWSWIRE) -- Mercury Biomed, a company developing a novel approach to managing core body temperature, announces it has won a non-dilutive Phase I Small Business Technology Transfer (STTR) grant through the National Institute of General Medical Sciences (NIGMS) for $225,000. The award (R41GM119871) will enable Mercury to accelerate commercialization of its first device, a disruptive solution for warming patients in the peri-operative environment. “Managing core body temperature safely and effectively in surgical procedures remains a big challenge, and Mercury’s air-free patient warming solution is designed for physicians and hospitals transitioning to value-based care and alternative payment models,” explains Brian Patrick, Mercury Co-Founder. Fifty three million patients undergo general anesthesia procedures each year and run the risk of life-threatening complications due to rapid reduction of core body temperature in the Operating Room. Warming patients during surgery has become standard of care, but Mercury’s approach is vastly different and considerably smarter than existing alternatives. Mercury’s WarmSmart system, in contrast to alternative methods, works in-concert with the body’s intrinsic thermoregulatory function to noninvasively warm the body core. WarmSmart is physiologically more efficient, less intrusive to the surgical field, easy-to-use, and eliminates the risk of surgical site infection associated with current forced-air warming devices. The global market for patient temperature management solutions is $2.5 billion per year. "Mercury is deeply appreciative of the assistance provided by the NIH and NIGMS through this STTR program," said Brad Pulver, CEO of Mercury Biomed. "Our mission is to provide the smartest, safest, and most clinically effective solution to help hospitals and surgeons who, in a growing number of cases, are required to accept financial responsibility for patient outcomes. This award expedites our time to market and allows us to continue our rapid progress and initial success toward this goal.” WarmSmart was developed from research conducted at The University of Texas at Austin. Professor Ken Diller, Inventor, Principal Investigator, and Mercury’s Chief Science Officer commented, “An award from this highly competitive STTR program is a testimony to the importance of improving safety and surgery outcomes, and our disruptive discovery for the field of human temperature management. The support of the NIH is validating to our efforts and will be instrumental in translating our technology from my bio heat transfer lab to commercial application." Based on the results achieved in Phase I and the scientific and technical merit and commercial potential of Mercury’s project, an additional potential $1.5M in non-dilutive funds may be awarded in Phase II.  During Phase II, Mercury would begin its second pivotal clinical trial with its partner, the Cleveland Clinic, where Drs. Daniel Sessler and Andrea Kurz, along with Dr. Wilton Levine (Mass General) will oversee Mercury’s clinical efforts. The grant is Mercury’s second major non-dilutive funding victory, as it was previously funded by the Ohio Third Frontier program, placing Mercury in rare company as a winner of both awards. About Mercury Biomed: Based in Cleveland, Ohio, Mercury Biomed, LLC is commercializing its proprietary Smart Temperature Management System™ technology, a breakthrough non-invasive and holistic approach to cooling and warming patients when and where it matters most. Founded in 2015, the company is led by top scientific experts and entrepreneurs in the field of therapeutic temperature management. Mercury Biomed’s WarmSmart product is currently in clinical trials and is targeted for a 2018 launch, pending FDA 510(k) clearance.  www.mercurybiomed.com About the National Institutes of Health (NIH) STTR & SBIR Programs: The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are designed to award federal research grants to small businesses conducting biomedical research. The goal of these Programs is to spur technological innovation leading to commercialization of novel innovative medical technologies to improve public health. Both Programs share this common goal, but differ somewhat in eligibility and research execution criteria. The NIH STTR and SBIR Programs are highly competitive, as reflected in the following award data statistics for Phase I STTR awards for fiscal years 2007-2016 available at https://sbir.nih.gov/statistics/award-data. For more information about the NIH STTR and SBIR Programs, please go to https://sbir.nih.gov/.


News Article | May 11, 2017
Site: globenewswire.com

CLEVELAND, May 11, 2017 (GLOBE NEWSWIRE) -- Mercury Biomed, a company developing a novel approach to managing core body temperature, announces it has won a non-dilutive Phase I Small Business Technology Transfer (STTR) grant through the National Institute of General Medical Sciences (NIGMS) for $225,000. The award (R41GM119871) will enable Mercury to accelerate commercialization of its first device, a disruptive solution for warming patients in the peri-operative environment. “Managing core body temperature safely and effectively in surgical procedures remains a big challenge, and Mercury’s air-free patient warming solution is designed for physicians and hospitals transitioning to value-based care and alternative payment models,” explains Brian Patrick, Mercury Co-Founder. Fifty three million patients undergo general anesthesia procedures each year and run the risk of life-threatening complications due to rapid reduction of core body temperature in the Operating Room. Warming patients during surgery has become standard of care, but Mercury’s approach is vastly different and considerably smarter than existing alternatives. Mercury’s WarmSmart system, in contrast to alternative methods, works in-concert with the body’s intrinsic thermoregulatory function to noninvasively warm the body core. WarmSmart is physiologically more efficient, less intrusive to the surgical field, easy-to-use, and eliminates the risk of surgical site infection associated with current forced-air warming devices. The global market for patient temperature management solutions is $2.5 billion per year. "Mercury is deeply appreciative of the assistance provided by the NIH and NIGMS through this STTR program," said Brad Pulver, CEO of Mercury Biomed. "Our mission is to provide the smartest, safest, and most clinically effective solution to help hospitals and surgeons who, in a growing number of cases, are required to accept financial responsibility for patient outcomes. This award expedites our time to market and allows us to continue our rapid progress and initial success toward this goal.” WarmSmart was developed from research conducted at The University of Texas at Austin. Professor Ken Diller, Inventor, Principal Investigator, and Mercury’s Chief Science Officer commented, “An award from this highly competitive STTR program is a testimony to the importance of improving safety and surgery outcomes, and our disruptive discovery for the field of human temperature management. The support of the NIH is validating to our efforts and will be instrumental in translating our technology from my bio heat transfer lab to commercial application." Based on the results achieved in Phase I and the scientific and technical merit and commercial potential of Mercury’s project, an additional potential $1.5M in non-dilutive funds may be awarded in Phase II.  During Phase II, Mercury would begin its second pivotal clinical trial with its partner, the Cleveland Clinic, where Drs. Daniel Sessler and Andrea Kurz, along with Dr. Wilton Levine (Mass General) will oversee Mercury’s clinical efforts. The grant is Mercury’s second major non-dilutive funding victory, as it was previously funded by the Ohio Third Frontier program, placing Mercury in rare company as a winner of both awards. About Mercury Biomed: Based in Cleveland, Ohio, Mercury Biomed, LLC is commercializing its proprietary Smart Temperature Management System™ technology, a breakthrough non-invasive and holistic approach to cooling and warming patients when and where it matters most. Founded in 2015, the company is led by top scientific experts and entrepreneurs in the field of therapeutic temperature management. Mercury Biomed’s WarmSmart product is currently in clinical trials and is targeted for a 2018 launch, pending FDA 510(k) clearance.  www.mercurybiomed.com About the National Institutes of Health (NIH) STTR & SBIR Programs: The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are designed to award federal research grants to small businesses conducting biomedical research. The goal of these Programs is to spur technological innovation leading to commercialization of novel innovative medical technologies to improve public health. Both Programs share this common goal, but differ somewhat in eligibility and research execution criteria. The NIH STTR and SBIR Programs are highly competitive, as reflected in the following award data statistics for Phase I STTR awards for fiscal years 2007-2016 available at https://sbir.nih.gov/statistics/award-data. For more information about the NIH STTR and SBIR Programs, please go to https://sbir.nih.gov/.


News Article | May 11, 2017
Site: globenewswire.com

CLEVELAND, May 11, 2017 (GLOBE NEWSWIRE) -- Mercury Biomed, a company developing a novel approach to managing core body temperature, announces it has won a non-dilutive Phase I Small Business Technology Transfer (STTR) grant through the National Institute of General Medical Sciences (NIGMS) for $225,000. The award (R41GM119871) will enable Mercury to accelerate commercialization of its first device, a disruptive solution for warming patients in the peri-operative environment. “Managing core body temperature safely and effectively in surgical procedures remains a big challenge, and Mercury’s air-free patient warming solution is designed for physicians and hospitals transitioning to value-based care and alternative payment models,” explains Brian Patrick, Mercury Co-Founder. Fifty three million patients undergo general anesthesia procedures each year and run the risk of life-threatening complications due to rapid reduction of core body temperature in the Operating Room. Warming patients during surgery has become standard of care, but Mercury’s approach is vastly different and considerably smarter than existing alternatives. Mercury’s WarmSmart system, in contrast to alternative methods, works in-concert with the body’s intrinsic thermoregulatory function to noninvasively warm the body core. WarmSmart is physiologically more efficient, less intrusive to the surgical field, easy-to-use, and eliminates the risk of surgical site infection associated with current forced-air warming devices. The global market for patient temperature management solutions is $2.5 billion per year. "Mercury is deeply appreciative of the assistance provided by the NIH and NIGMS through this STTR program," said Brad Pulver, CEO of Mercury Biomed. "Our mission is to provide the smartest, safest, and most clinically effective solution to help hospitals and surgeons who, in a growing number of cases, are required to accept financial responsibility for patient outcomes. This award expedites our time to market and allows us to continue our rapid progress and initial success toward this goal.” WarmSmart was developed from research conducted at The University of Texas at Austin. Professor Ken Diller, Inventor, Principal Investigator, and Mercury’s Chief Science Officer commented, “An award from this highly competitive STTR program is a testimony to the importance of improving safety and surgery outcomes, and our disruptive discovery for the field of human temperature management. The support of the NIH is validating to our efforts and will be instrumental in translating our technology from my bio heat transfer lab to commercial application." Based on the results achieved in Phase I and the scientific and technical merit and commercial potential of Mercury’s project, an additional potential $1.5M in non-dilutive funds may be awarded in Phase II.  During Phase II, Mercury would begin its second pivotal clinical trial with its partner, the Cleveland Clinic, where Drs. Daniel Sessler and Andrea Kurz, along with Dr. Wilton Levine (Mass General) will oversee Mercury’s clinical efforts. The grant is Mercury’s second major non-dilutive funding victory, as it was previously funded by the Ohio Third Frontier program, placing Mercury in rare company as a winner of both awards. About Mercury Biomed: Based in Cleveland, Ohio, Mercury Biomed, LLC is commercializing its proprietary Smart Temperature Management System™ technology, a breakthrough non-invasive and holistic approach to cooling and warming patients when and where it matters most. Founded in 2015, the company is led by top scientific experts and entrepreneurs in the field of therapeutic temperature management. Mercury Biomed’s WarmSmart product is currently in clinical trials and is targeted for a 2018 launch, pending FDA 510(k) clearance.  www.mercurybiomed.com About the National Institutes of Health (NIH) STTR & SBIR Programs: The NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are designed to award federal research grants to small businesses conducting biomedical research. The goal of these Programs is to spur technological innovation leading to commercialization of novel innovative medical technologies to improve public health. Both Programs share this common goal, but differ somewhat in eligibility and research execution criteria. The NIH STTR and SBIR Programs are highly competitive, as reflected in the following award data statistics for Phase I STTR awards for fiscal years 2007-2016 available at https://sbir.nih.gov/statistics/award-data. For more information about the NIH STTR and SBIR Programs, please go to https://sbir.nih.gov/.


Global Operating Room Equipment Market by Products, Geography, Trends and Forecast to 2021, New Report by iHealthcareAnalyst, Inc. Operating Room Equipment Market by Equipment Used in Operating Room (Operating Room Integration Systems, Lights, Tables, Surgical Booms and Surgical Imaging Display Systems) and Forecast 2017-2021 Maryland Heights, MO, May 09, 2017 --( Browse Operating Room Equipment Market by Equipment Used in Operating Room (Operating Room Integration Systems, Lights, Tables, Surgical Booms and Surgical Imaging Display Systems) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/operating-room-equipment-market/ The global operating room equipment market report estimates the market size (Revenue USD million - 2014 to 2021) for market segments based on equipment used in operating room and forecasts growth trends (CAGR% - 2017 to 2021). The global operating room equipment market report estimates the market size (Revenue USD million – 2014 to 2021) for market segments based on equipment used in operating room (operating tables, operating room lights, surgical booms, operating room integration systems and surgical imaging displays) and forecasts growth trends (CAGR% – 2017 to 2021). The global operating room equipment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global operating room equipment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the global operating room equipment market and included in this report are Getinge Group, Steris Corporation, Stryker Corporation, Berchtold Corporation, Skytron, LLC, TRUMPF GmbH + Co. KG, Karl Storz GmbH & Co. KG, Eschmann Equipment, Mizuho OSI and NDS Surgical Imaging, LLC. 1. Product Type 1.1. Operating Room Integration Systems 1.2. Operating Room Lights 1.3. Operating Tables 1.4. Surgical Booms 1.5. Surgical Imaging Displays 2. Company Profiles 2.1. Berchtold Corporation 2.2. Eschmann Equipment 2.3. Getinge Group 2.4. Karl Storz GmbH & Co. KG 2.5. Mizuho OSI 2.6. NDS Surgical Imaging, LLC 2.7. Skytron, LLC 2.8. Steris Corporation 2.9. Stryker Corporation 2.10. TRUMPF GmbH Co. KG To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/operating-room-equipment-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, May 09, 2017 --( PR.com )-- Within hospitals, surgical operations are carried out in a sterile environment in an operating room (OR) or operating theater or operating suite which consists of operating room integration systems, lights, tables, surgical booms and surgical imaging display systems. The rising concerns about reduction in healthcare spending and achieving accurate surgical outcomes, healthcare providers across the globe are focusing on enhancing operating room efficiency, while minimizing the required resources and related costs. Some of the factors that are expected to drive market growth during the forecast period include gradual increase in number of ambulatory surgical centers worldwide, increasing demand for hybrid operating rooms and technological advancement in safe and cost-effective operating procedures.Browse Operating Room Equipment Market by Equipment Used in Operating Room (Operating Room Integration Systems, Lights, Tables, Surgical Booms and Surgical Imaging Display Systems) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/operating-room-equipment-market/The global operating room equipment market report estimates the market size (Revenue USD million - 2014 to 2021) for market segments based on equipment used in operating room and forecasts growth trends (CAGR% - 2017 to 2021). The global operating room equipment market report estimates the market size (Revenue USD million – 2014 to 2021) for market segments based on equipment used in operating room (operating tables, operating room lights, surgical booms, operating room integration systems and surgical imaging displays) and forecasts growth trends (CAGR% – 2017 to 2021). The global operating room equipment market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global operating room equipment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.Major players operating in the global operating room equipment market and included in this report are Getinge Group, Steris Corporation, Stryker Corporation, Berchtold Corporation, Skytron, LLC, TRUMPF GmbH + Co. KG, Karl Storz GmbH & Co. KG, Eschmann Equipment, Mizuho OSI and NDS Surgical Imaging, LLC.1. Product Type1.1. Operating Room Integration Systems1.2. Operating Room Lights1.3. Operating Tables1.4. Surgical Booms1.5. Surgical Imaging Displays2. Company Profiles2.1. Berchtold Corporation2.2. Eschmann Equipment2.3. Getinge Group2.4. Karl Storz GmbH & Co. KG2.5. Mizuho OSI2.6. NDS Surgical Imaging, LLC2.7. Skytron, LLC2.8. Steris Corporation2.9. Stryker Corporation2.10. TRUMPF GmbH Co. KGTo request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/operating-room-equipment-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


News Article | May 15, 2017
Site: www.businesswire.com

SAN FRANCISCO--(BUSINESS WIRE)--AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS) (the "Company", "AMS"), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the first quarter of 2017. For the three months ended March 31, 2017, medical services revenue increased 16.0% to $4,914,000 compared to medical services revenue of $4,238,000 for the first quarter of 2016. First quarter revenue for the Company's initial proton therapy system installed at The Marjorie and Leonard Williams Center for Proton Therapy at UF Health Cancer Center-Orlando Health in Florida was $1,155,000. Revenue for the Company's Gamma Knife operations decreased to $3,619,000 for the first quarter of 2017 compared to $4,125,000 for the first quarter of 2016, primarily because two sites were offline during this year's first quarter for Cobalt-60 reload. Net income attributable to the Company for the first quarter of 2017 increased to $293,000, or $0.05 per share. This compares to net income attributable to the Company for the first quarter of 2016 of $51,000, or $0.01 per share. Medical services gross margin for the first quarter of 2017 increased to 47.7% of revenue, compared to medical services gross margin of 40.9% of revenue for the first quarter of 2016, primarily reflecting the increase in revenue from proton therapy. Operating income increased 51.1% to $754,000 for the first quarter of 2017 compared to operating income of $499,000 for the same period a year earlier. Income before income taxes increased 91.4% to $758,000 for the first quarter of 2017 compared to $396,000 for the first quarter of 2016. Non-GAAP pre-tax income, net of income attributable to non-controlling interest, was $509,000 for the first quarter of 2017. This compares to non-GAAP pre-tax income, net of income attributable to non-controlling interest, of $115,000 for the first quarter of 2016. Selling and administrative expenses for the first quarter of 2017 increased to $1,139,000, compared to selling and administrative expenses of $949,000 for the first quarter of 2016. Interest expense increased to $453,000 for the first quarter of 2017, compared to interest expense of $285,000 for the first quarter of 2016, primarily reflecting the addition of the proton center in Orlando. Adjusted EBITDA, a non-GAAP financial measure, was $2,616,000 for the first quarter of 2017, compared to $2,129,000 for the first quarter of 2016. Please refer to the financial statements included with this press release for a reconciliation of GAAP to this non-GAAP financial measure. At March 31, 2017, cash and cash equivalents was $2,403,000, compared to $2,871,000 at December 31, 2016. Shareholders' equity at March 31, 2017 was $27,774,000, or $4.87 per outstanding share. This compares to shareholders' equity at December 31, 2016 of $27,173,000, or $4.97 per outstanding share. Chairman and Chief Executive Officer Ernest A. Bates, M.D. said, "Patient treatments that began in April 2016 at our proton center at UF Health Cancer Center-Orlando Health continue to drive improved financial performance for AMS. Treatment volume at this center increased to 1,220 fractions in the first quarter, compared to 1,019 fractions performed in last year's fourth quarter, 869 fractions performed in the third quarter and 442 fractions performed in the second quarter. The reliability and throughput of the MEVION S250 proton system we supplied Orlando Health is meeting or exceeding our expectations, and we believe there is room for further growth in treatment volume. "The decrease in revenue in our Gamma Knife business in this year's first quarter was the anticipated consequence of routine Cobalt-60 reload at two of our centers. As previously announced, we will lose one of our sites due to the expiration of its contract term in this year's second quarter; however, we expect the Gamma Knife® Perfexion™ system we recently contracted to supply to Bryan Medical Center in Lincoln, Nebraska to begin treating patients in this year's second half. We also expect patient treatments to begin in this year's third quarter on a Gamma Knife located at the Air Force Hospital in Lima, Peru. "We are focused on taking advantage of the attractive growth opportunities available to us in both our proton and Gamma Knife businesses. Building on the success we have achieved to date, we are confident that AMS will deliver further growth in the years ahead." American Shared has scheduled a conference call at 12:00 p.m. PDT (3:00 p.m. EDT) today. To participate in the live call, dial (800) 588-4973 at least 5 minutes prior to the scheduled start time, and mention confirmation number 4493 2897. A simultaneous WebCast of the call may be accessed through the Company's website, www.ashs.com, or www.streetevents.com (institutional investors). A replay will be available for 14 days at these same internet addresses, or by dialing 888-843-7419 and entering 4493 2897# when prompted. American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT and IMRT systems. AMS owns a common stock investment in Mevion Medical Systems, Inc., developer of the compact MEVION S250 Proton Therapy System. This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services (including statements regarding the expected continued growth in treatment volume of the MEVION S250 system, the expansion of the Company's proton therapy business, the growth of the Company, and the timing of treatments by new Gamma Knife systems) which involve risks and uncertainties including, but not limited to, the risks of variability of financial results between quarters, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of investing in Mevion Medical Systems, Inc., and the risks of the timing, financing, and operations of the Company’s proton therapy business. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and the definitive Proxy Statement for the Annual Meeting of Shareholders to be held on June 27, 2017. None of Adjusted EBITDA and non-GAAP pre-tax income, the non-GAAP measures presented in this press release and supplementary information, is a measure of performance under the accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures should not be considered as substitute for, and investors should also consider, income (loss) before income taxes, income from operations, net income attributable to the Company, earnings (loss) per share and other measures of performance as defined by GAAP as indicators of the Company's performance or profitability. We use these non-GAAP financial measures as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain expenses and charges that may not be indicative of the operating results of our recurring core business, such as the loss on early extinguishment of debt. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Medical Equipment Market Research Reports, Competitive Analytics, Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. Medical Equipment Market reports include 3D Printing, Apheresis Equipment, Capnography Equipment, Casting and Splinting Equipment, Dental Equipment, Electrophoresis Equipment and Supplies, Lyophilization Equipment and Services, Medical Equipment Calibration Services, Medical Equipment Rental, Medical Gases and Equipment Services, Medical Imaging Equipment, Mortuary Equipment, Multiparameter Patient Monitoring Equipment, etc. Maryland Heights, MO, May 21, 2017 --( The global medical equipment market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global market research reports are divided by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global reports also provide detailed market landscape (market drivers, restraints, opportunities), market attractiveness and profitability analysis as well as profiles of major competitors in the global market which includes company overview, financial snapshot, key products, technologies and services offered, and recent developments. Browse Global Medical Equipment Market Reports, Competitive Analytics, Growth Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. at https://www.ihealthcareanalyst.com/reports/medical-equipment/ Table of Contents 1. Introduction 2. Executive Summary 2.1. Market Size Estimation (Revenue USD Million, 2014-2021) 2.2. Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021) 3. Research Methodology 4. Market Landscape 4.1. Market Dynamics 4.1.1. Drivers 4.1.2. Barriers 4.1.3. Opportunities 4.2. Market Share Analysis 4.2.1. Companies 4.2.2. Equipment 4.3. Market Trends Analysis 4.3.1. Key success factors 4.3.2. Market Growth Rate 4.4. Market Attractiveness Analysis 4.5. Market Profitability Analysis 4.5.1. Buyer power 4.5.2. Supplier power 4.5.3. Barriers to entry 4.5.4. Threat of substitute products 4.5.5. Rivalry among firms in the industry 4.5.6. Distribution Channels 5. Market Segmentation 5.1. Equipment or Brand Type 5.2. Modality Type 5.3. Indication Type 5.4. Procedure Type 5.5. Technology 5.6. Diagnostics, Therapeutic or Surgical Application 5.7. End User Groups 6. Geography (Region, Country) 6.1. North America (U.S., Canada) 6.2. Latin America (Brazil, Mexico, Rest of LA) 6.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 6.4. Asia Pacific (Japan, China, India, Rest of APAC) 6.5. Rest of the World 7. Regulatory Overview 7.1. Device Classification I, II, III, IV 7.2. Device (FDA, EMEA) Approvals 8. Company Profiles 8.1. Company Overview 8.2. Financial Snapshot (FY 2014-2016) 8.3. Product Portfolio 8.4. Business Strategies 8.5. Recent Developments 9. Recommendations 10. References To request Table of Contents and Sample Pages of these reports visit: https://www.ihealthcareanalyst.com/reports/medical-equipment/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, May 21, 2017 --( PR.com )-- The published titles of Medical Equipment Market reports by iHealthcareAnalyst, Inc. include 3D Printing, Apheresis Equipment, Capnography Equipment, Casting and Splinting Equipment, Dental Equipment, Electrophoresis Equipment and Supplies, Lyophilization Equipment and Services, Medical Equipment Calibration Services, Medical Equipment Rental, Medical Gases and Equipment Services, Medical Imaging Equipment, Mortuary Equipment, Multiparameter Patient Monitoring Equipment, Operating Room Equipment, Orthodontic Equipment and Consumables, Prenatal, Fetal and Neonatal Equipment, Spectrometry Equipment, Spectrometry, Sterile Medical Packaging, Sterilization Equipment, Sterilizers, Surgical, Dental Care and Equipment Disinfectors, Surgical Equipment, Surgical Navigation Systems, Teleradiology, and Urodynamics Equipment and Disposables.The global medical equipment market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global market research reports are divided by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global reports also provide detailed market landscape (market drivers, restraints, opportunities), market attractiveness and profitability analysis as well as profiles of major competitors in the global market which includes company overview, financial snapshot, key products, technologies and services offered, and recent developments.Browse Global Medical Equipment Market Reports, Competitive Analytics, Growth Trends and Forecast 2017-2021 by iHealthcareAnalyst, Inc. at https://www.ihealthcareanalyst.com/reports/medical-equipment/Table of Contents1. Introduction2. Executive Summary2.1. Market Size Estimation (Revenue USD Million, 2014-2021)2.2. Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)3. Research Methodology4. Market Landscape4.1. Market Dynamics4.1.1. Drivers4.1.2. Barriers4.1.3. Opportunities4.2. Market Share Analysis4.2.1. Companies4.2.2. Equipment4.3. Market Trends Analysis4.3.1. Key success factors4.3.2. Market Growth Rate4.4. Market Attractiveness Analysis4.5. Market Profitability Analysis4.5.1. Buyer power4.5.2. Supplier power4.5.3. Barriers to entry4.5.4. Threat of substitute products4.5.5. Rivalry among firms in the industry4.5.6. Distribution Channels5. Market Segmentation5.1. Equipment or Brand Type5.2. Modality Type5.3. Indication Type5.4. Procedure Type5.5. Technology5.6. Diagnostics, Therapeutic or Surgical Application5.7. End User Groups6. Geography (Region, Country)6.1. North America (U.S., Canada)6.2. Latin America (Brazil, Mexico, Rest of LA)6.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)6.4. Asia Pacific (Japan, China, India, Rest of APAC)6.5. Rest of the World7. Regulatory Overview7.1. Device Classification I, II, III, IV7.2. Device (FDA, EMEA) Approvals8. Company Profiles8.1. Company Overview8.2. Financial Snapshot (FY 2014-2016)8.3. Product Portfolio8.4. Business Strategies8.5. Recent Developments9. Recommendations10. ReferencesTo request Table of Contents and Sample Pages of these reports visit: https://www.ihealthcareanalyst.com/reports/medical-equipment/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


While the markets for traditional devices such as peripheral inserted central catheters (PICCs) and central venous catheters (CVCs) are maturing, companies are actively investing in the development of new technological features that have maintained average selling prices (ASPs) for these devices. In the PIVC market, midline catheters are re-emerging as a viable alternative to short PIVCs when a longer dwell time is required. The competition in this market has spurred companies to differentiate their products in order to gain market share. This has consistently led to unique, premium-priced products. Some of the new technology will strive to increase lumen number to allow for multiple functions with the same catheter. The more significant technological advancements will be in electrocardiogram (ECG) tip location. The increasing use of ultrasound has led to significant growth in the use of PICCs and PIVCs. C.R. Bard, recently acquired by Becton Dickinson (BD), is the leading competitor in the Australian vascular access device and accessories market due to their strong market share in the implantable ports and PICCs market, but also held a significant share in the port needles market. The company is present in all of the vascular access segments, especially after their recent acquisition by BD. Becton Dickinson has been extremely aggressive in their marketing and acquisition strategies in the vascular access market. In addition, the company continues to lead the way with new technologies, such as power-injectable devices. Bard in particular takes advantage of the crossover between market segments and has been able to increase their presence in the rapidly growing complementary markets. Moreover, Bard remains the only company in Australia with an ECG-based catheter tip confirmation, which is essential for efficient PICC placement. Additional competitors in this market include B. Braun, Smiths Medical, Teleflex, Cook Medical, Medcomp, Angiodynamics, Medtronic and Baxter among others. More on the vascular access market in Australia can be found in a series of reports published by iData Research entitled the Australia Market Report Suite for Vascular Access Devices and Accessories. The market includes implantable ports, port needles, central venous catheters (CVCs), peripherally inserted central catheters (PICCs), peripheral intravenous catheters (PIVCs) and dialysis catheters. The iData report series on vascular access devices covers the U.S., China, India, Japan, Australia, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about robotic surgery systems market data, register online or email us at info@idataresearch.net for an Australia Market Report Suite for Vascular Access Devices and Accessories brochure and synopsis. iData Research (www.idataresearch.com) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ophthalmics, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Operating Room Equipment, Surgical Microscopes, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cr-bard-becton-dickinson-lead-australia-vascular-access-market-due-to-new-technological-advancements-300458629.html


Despite increasing unit sales, increased competitiveness within the total patient monitoring market has had a negative impact on market growth. The entry of low cost foreign competition has been especially disruptive. However, the long-term prospects remain positive as demand for quality patient monitoring solutions will enable unit sales growth to outpace pricing pressure. Philips Healthcare is the leading competitor in the Australian patient monitoring market. The company competes in the multi-parameter vital sign monitoring market, wireless telemetry, pulse oximetry and fetal/neonatal monitoring markets. Their IntelliVue™ and SureSigns™ product lines range from low to high-acuity and have flexible product designs ranging from extremely compact to portable bedside units. GE Healthcare is the second leading competitor in the Australian patient monitoring market. GE offers an extensive product line that not only includes a range of low- to high-acuity monitoring devices, but also telemetry devices and networking solutions. Their product lines include the CARESCAPE™ B series and new B40™ patient monitors which can feed into the CARESCAPE™ central stations and mobile viewers to access patient information. Additional competitors in the Australia patient monitoring market include Dräger Medical, Medtronic, Mindray, Nihon Kohden, Natus Medical, Compumedics, Welch Allyn, Spacelabs Healthcare, Nonin and Smiths Medical among others. More on the patient monitoring device market in Australia can be found in a series of reports published by iData Research entitled the Australia Market Report Suite for Patient Monitoring Equipment. The suite covers reports on the following markets: multi-parameter vital signs monitoring, wireless ambulatory telemetry monitoring, telehealth, electromyogram monitoring, electroencephalogram monitoring, fetal and neonatal monitoring, pulse oximetry and blood pressure monitoring devices. The iData report series on patient monitoring devices covers the U.S., China, Australia, India, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about patient monitoring device market data, register online or email us at info@idataresearch.net for an Australia Market Report Suite for Patient Monitoring Equipment brochure and synopsis. iData Research (www.idataresearch.com) is an international market consulting research firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/philips-and-ge-healthcare-lead-the-australia-patient-monitoring-equipment-market-due-to-the-adoption-of-less-invasive-more-accessible-patient-centric-device-configurations-300464048.html


The ASP decline is reinforced by competition among discount and value companies. However, the moderate growth rate of the U.S. dental implant industry has spurred the development and acceptance of technologies that facilitate dental implant placement and restoration. In turn, these technological advancements will further drive dental implant replacement rates. Additionally, technological advancements incorporated into dental software suites are set to drive sales, especially software that falls under premium brands. However, downward price pressure and the market entry of low-cost competitors will continue to offset gains in unit sales, resulting in moderate market values. The market has been restructuring, with discounted and value brands gaining popularity in the market. Generic and imitation abutments are growing more acceptable. Instrument kits are increasingly being given away. Treatment planning software is now bundled to help retain loyal customers. Discounted surgical guides are growing more prevalent. These market limiters have largely impacted market value and revenue potential in the overall U.S. market. The dental implant fixtures and final abutments market in the U.S. is largely controlled by three main companies: Nobel Biocare, Straumann and Dentsply Sirona. In addition to their current dominance in the market, they are also very active with ongoing acquisitions to further secure their leading positions. The leading competitors have also been able to maintain their ranking through a history of brand loyalty. The dental market is dominated by specialists such as periodontists and oral surgeons, who generally prefer premium brands. As a consequence, the premium companies are expected to maintain their dominance in upcoming years. As discount and value brands continue to emerge on the market, premium leaders are expected to continually lose market share. However, the market leaders have engaged in price cutting and bundling of large-scale purchases to remain competitive. Additional competitors in the U.S. dental implant fixtures market include Zimmer Biomet, BioHorizons, Implant Direct and MIS Implants among others. More on the dental implant market in the U.S. can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Dental Implant Fixtures and Final Abutments. The suite covers reports on the following markets: dental implant fixtures, final abutments, dental implant instrument kits, treatment planning software and surgical guides. The iData report series on dental implants covers the U.S., Argentina, Brazil, Mexico, China, Australia, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about dental implant market data, register online or email us at info@idataresearch.net for a U.S. Market Report Suite for Dental Implant Fixtures and Final Abutments brochure and synopsis. iData Research (www.idataresearch.com) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nobel-biocare-straumann-dentsply-sirona-lead-us-dental-implant-fixtures-market-despite-pricing-pressure-from-low-cost-competitors-300464649.html

Loading Operating Room collaborators
Loading Operating Room collaborators